Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 168

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer

Khongkow, Mattaka, Olmos, Yolanda, Gong, Chun, Gomes, Ana R., Monteiro, Lara J., Yagüe, Ernesto, Cavaco, Tania B., Khongkow, Pasarat, Man, Ellen P.S., Laohasinnarong, Sasiwan, Koo, Chuay-Yeng, Harada-Shoji, Narumi, Tsang, Janice W.-H., Coombes, R.Charles, Schwer, Bjoern, Khoo, Ui-Soon, Lam, Eric W.-F.·2013·Carcinogenesis

Abstract

In this study, we report the identification of a novel role of SIRT6 in both epirubicin and paclitaxel resistance in breast cancer. We found that SIRT6 protein levels are elevated in paclitaxel- and epirubicin-resistant MCF-7 cells compared with the parental sensitive cells. SIRT6 knockout and depletion sensitized cells to both paclitaxel and epirubicin treatment, whereas SIRT6 ectopic overexpression led to increased resistance to paclitaxel and epirubicin. Moreover, our data suggest that SIRT6 could be mediating epirubicin resistance through enhancing the DNA repair response to epirubicin-induced DNA damage. Clonogenic assays also revealed that mouse embryonic fibroblasts (MEFs) lacking SIRT6 have decreased long-term viability in response to epirubicin. The tumour suppressor FOXO3a increases its levels of acetylation in MEFs depleted of SIRT6, whereas its induction by epirubicin is attenuated in breast cancer cells overexpressing SIRT6. Further cell viability studies demonstrate that deletion of FOXO1/3/4 in MEFs can confer sensitivity to both paclitaxel and epirubicin, suggesting that SIRT6 reduces paclitaxel and epirubicin sensitivity, at least in part, through modulating FOXO acetylation and expression. Consistently, immunohistochemical analysis of 118 breast cancer patient samples revealed that high SIRT6 nuclear staining is significantly associated with poorer overall survival (P = 0.018; Kaplan-Meier analysis). Multivariate Cox analysis demonstrated that nuclear SIRT6 staining remained associated with death after correcting for tumour stage and lymph-node involvement (P = 0.033). Collectively, our data suggest that SIRT6 has a role in paclitaxel and epirubicin sensitivity via targeting FOXO proteins and that SIRT6 could be a useful biomarker and therapeutic target for paclitaxel- and epirubicin-resistant cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/carcin/bgt098

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 168

Metadata

Authors
Khongkow, M., Olmos, Y., Gong, C., Gomes, A. R., Monteiro, L. J., Yagüe, E., Cavaco, T. B., Khongkow, P., Man, E. P. S., Laohasinnarong, S., Koo, C.-Y., Harada-Shoji, N., Tsang, J. W.-H., Coombes, R. C., Schwer, B., Khoo, U.-S., & Lam, E. W.-F.
Venue
Carcinogenesis
Published
2013-03-20
Volume
34
Issue
7
Pages
1476-1486
ISSN
  • 0143-3334 (ISSN-L)
  • 1460-2180
OpenAlex
W2148899732
Cited by
168
References
6
FWCI
7.03
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. https://app.cochat.ai/papers/10.1093/carcin/bgt098
The paper
Khongkow, M., Olmos, Y., Gong, C., Gomes, A. R., Monteiro, L. J., Yagüe, E., Cavaco, T. B., Khongkow, P., Man, E. P. S., Laohasinnarong, S., Koo, C.-Y., Harada-Shoji, N., Tsang, J. W.-H., Coombes, R. C., Schwer, B., Khoo, U.-S., & Lam, E. W.-F. (2013). SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. Carcinogenesis. https://doi.org/10.1093/carcin/bgt098

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.